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Abstract
Objective: To evaluate cerebrospinal fluid (CSF) and serum neurofilament light
chain (NfL) levels in genetic frontotemporal dementia (FTD) as a potential bio-
marker in the presymptomatic stage and during the conversion into the symp-
tomatic stage. Additionally, to correlate NfL levels to clinical and neuroimaging
parameters. Methods: In this multicenter case–control study, we investigated
CSF NfL in 174 subjects (48 controls, 40 presymptomatic carriers and 86
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patients with microtubule-associated protein tau (MAPT), progranulin (GRN),
and chromosome 9 open reading frame 72 (C9orf72) mutations), and serum NfL
in 118 subjects (39 controls, 44 presymptomatic carriers, 35 patients). In 55
subjects both CSF and serum was determined. In two subjects CSF was avail-
able before and after symptom onset (converters). Additionally, NfL levels were
correlated with clinical parameters, survival, and regional brain atrophy.
Results: CSF NfL levels in patients (median 6762 pg/mL, interquartile range
3186–9309 pg/mL) were strongly elevated compared with presymptomatic carri-
ers (804 pg/mL, 627–1173 pg/mL, P < 0.001), resulting in a good diagnostic
performance to discriminate both groups. Serum NfL correlated highly with
CSF NfL (rs = 0.87, P < 0.001) and was similarly elevated in patients. Longitu-
dinal samples in the converters showed a three- to fourfold increase in CSF
NfL after disease onset. Additionally, NfL levels in patients correlated with dis-
ease severity, brain atrophy, annualized brain atrophy rate and survival.
Interpretation: NfL in both serum and CSF has the potential to serve as a bio-
marker for clinical disease onset and has a prognostic value in genetic FTD.
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Introduction
Mutations in the microtubule-associated protein tau
(MAPT), progranulin (GRN) or chromosome 9 open read-
ing frame 72 (C9orf72) genes are major causes of genetic
frontotemporal dementia (FTD) and are associated with
considerable clinical heterogeneity.1–5 The presymp-
tomatic stage offers a unique window to study the earliest
disease stages.6 Changes in neuroimaging biomarkers have
been found in presymptomatic FTD, similar to findings
in familial Alzheimer’s disease (AD) and Huntington’s
disease.6–9 However, fluid biomarkers determining disease
onset and progression are lacking, which are essential for
forthcoming trials on disease modifying treatments. Neu-
rofilament light chain (NfL) in cerebrospinal fluid (CSF)
is elevated in FTD, and other neurodegenerative diseases
such as amyotrophic lateral sclerosis (ALS), AD, and vas-
cular dementia, and dynamically decreases in response to
anti-inflammatory treatments in multiple sclerosis.10–14 In
contrast, small series of presymptomatic carriers of FTD-
causing mutations have shown low CSF NfL levels.10,15
NfL is one of the three subunits of neurofilaments, which
are the major constituent of the neuroaxonal cytoskeleton
and are essential for axonal growth, transport, and sig-
nalling pathways.16,17 CSF NfL has been correlated with
disease severity, disease progression, and brain atrophy in
neurodegenerative diseases.10,13,18 Blood-derived NfL
levels have proven to highly correlate with CSF NfL in
ALS.18 An important question is whether NfL levels may
serve as a biomarker for conversion from presymptomatic
to symptomatic genetic FTD and be useful in tracking
disease severity and progression.
To evaluate the potential of NfL levels as a biomarker
in genetic FTD, we determined CSF and serum NfL in
presymptomatic carriers and patients with pathogenic
mutations in MAPT, GRN or C9orf72, and correlated
these levels with clinical and neuroimaging measures.
Methods
Subjects
For this study, three subject groups were included from
11 centers collaborating in the Genetic FTD Initiative
(GENFI)19: (1) patients with FTD caused by a pathogenic
mutation in GRN, MAPT or C9orf72 (n = 102); (2)
presymptomatic carriers of a pathogenic mutation
(n = 63); and (3) cognitively healthy subjects without
mutation (controls, n = 73). A pathogenic C9orf72 expan-
sion was defined as more than 30 repeats.5 For GRN, only
nonsense mutations were included (Table 1), for MAPT,
published pathogenic mutations and those predicted as
pathogenic were taken into account (software package
Alamut v2.6.1, Interactive Biosoftware, Rouen, France;
Table 1). Participants were recruited as part of GENFI
(n = 126) or ascertained before participation in GENFI
(n = 112). Participants were either patients with a muta-
tion, or known presymptomatic carriers, or 50% at-risk
individuals (presymptomatic carriers and controls), or
cognitively healthy family members without a mutation
(controls). At-risk individuals are first-degree relatives of
a known carrier of a pathogenic mutation. Genotyping of
all participants was performed at local sites and clinical
investigators were blinded for the mutation status of at-
risk individuals. At-risk individuals and control subjects
underwent neuropsychological examination. Subjects were
categorized as presymptomatic or symptomatic according
to criteria at the time of inclusion.20–22 At-risk individuals
were followed yearly or two yearly to assess conversion
into symptomatic FTD. We defined conversion as the
presence of symptoms of behavioral variant FTD
(bvFTD), primary progressive aphasia (PPA) or amnestic
FTD as reported by informants and supported by neu-
ropsychological assessment and neuroimaging. Disease
onset in patients (n = 102) and converters (n = 4) was
defined as the moment of first symptoms noted by a care-
giver. In presymptomatic carriers, estimated time from
onset was calculated as age at sample collection minus
mean familial age at onset, resulting in a negative mea-
sure in carriers younger than the estimated onset derived
from onset ages in their family.6 Mini-Mental State
Examination (MMSE) was used to measure global cogni-
tion,23 disease severity was assessed by the Clinical
Dementia Rating scale (CDR) including, if available, the
sum of boxes (CDR-SB);24 we only considered scale mea-
surements within 90 days of biosample collection. In
seven subjects (five CSF, one serum, one both; five
C9orf72, two GRN mutations)25 ALS-symptoms were pre-
sent at sample collection; five of them met El Escorial cri-
teria at collection, the other two 6 months after
collection.26 No ALS-patients without FTD symptoms
were included.
Local ethics committees at each site approved the study
and all participants (or a legal representative) provided
written informed consent at enrollment.
Procedures
CSF (n = 179) was collected according to standardized
local procedures. Serum samples were collected from
Dutch participants only (n = 120). Both CSF and serum
collection within 1 year were available in 57 out of 61
subjects with both CSF and serum (same day n = 37,
range 0–360 days). Longitudinal CSF samples were avail-
able in five subjects, including converters; in one con-
verter a third CSF sample was available. T1-weighted
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MRI-images within 6 months of CSF collection were
available in 101 subjects and a follow-up scan in 22 sub-
jects. Detailed data on available biosamples and MRI
scans in the three subgroups after exclusion of outliers
(see Statistical analysis) are presented in Figure S1. Gray
matter volumes were determined by anatomical parcella-
tion of the whole brain, using a multiatlas segmentation
propagation approach,27,28 with the anatomical definitions
following the brainCOLOR protocol for the cortical
regions and Neuromorphometrics protocol for subcortical
regions and other structures.29,30 Regions-of-interest were
combined to calculate gray matter volumes of the frontal,
temporal, parietal, occipital, cingulate, and insular cor-
tices.28 Whole-brain volumes were calculated by combin-
ing all regions from the automated brain segmentation
method.30 All volumes are presented as percentage of
total intracranial volume (TIV). Atrophy rates were calcu-
lated as the percentage decrease in volume per year rela-
tive to baseline.
Laboratory methods
Measurements of NfL (in CSF and serum) were per-
formed in one laboratory (of CET respectively JK),
blinded to clinical information and mutation status. CSF
NfL was measured in duplicates using the enzyme-linked
immunosorbent assay (ELISA) of Uman Diagnostics
(Umea, Sweden), according to the manufacturer’s instruc-
tions over four different batches. Median intra-assay coef-
ficient of variation (CV) was 0.8% (range 0–66.5%),
inter-assay variability was below 20%. Serum NfL concen-
trations were measured in duplicate by an earlier
Table 1. Subject characteristics.
Controls
Presymptomatic
carriers Patients P-value
Number 71 62 101
Male gender 29 (41%) 23 (37%) 49 (49%) 0.32
Age at collection,
years (IQR)
54 (43–61) 49 (42–57) 59 (56–65) <0.0001
Age at onset,
years (range)
– 55 (46–70)1 56 (39–76)2 0.84
Disease duration,
years (IQR)
– – 2.0 (1.3–3.4)
Time to onset or
estimated onset,
years (IQR)
– 7.3 (2.5 – 13.2)1 –
MMSE (IQR) 29 (29–30) 30 (29–30) 25 (21–28) <0.0001
Concomitant ALS 0 0 7 0.005
Gene-specific information GRN C9orf72 MAPT GRN C9orf72 MAPT
Number per gene 343 14 144 535 29 196
Age at collection,
years (IQR)
55 (48–58) 45
(42–49)
41
(36–49)
60
(57–65)
61
(55–68)
57
(53–59)
Age at onset, years (range) 58 (47–76) 55
(39–75)
53
(42–70)
Disease duration,
years (IQR)
1.8 (1.1–2.6) 3.0
(2.0–5.0)
2.1
(1.5–3.7)
0.008
Time to onset or
estimated
onset, years (IQR)
5.8 (1.6–11.0) 11.5 (5.9–14.8) 7.3 (3.3–15.8) 0.19
Values are displayed as median (IQR). In the case of multiple samples in one subject, characteristics at first collection are displayed. IQR, interquar-
tile range; ALS, amyotrophic lateral sclerosis; MMSE, mini-mental state examination.
1Four presymptomatic subjects converted during follow-up into symptomatic stage after collection (2 with CSF, 1 with serum and 1 with CSF and
serum).
2In two patients the age at onset was unknown.
317 Ser82fs, 8 Gln125X, 5 Gly35fs, 2 Val411fs, 2 Cys416fs.
48 Pro301Leu, 3 Gly272Val, 1 Arg406Trp, 1 Leu135Arg, 1 Ser320Phe.
516 Thr272fs, 7 Ser82fs, 4 Gly35fs, 4 IVS1+5G>C, 3 Cys366fs, 3 Tyr294X, 2 Gln125X, 1 c.708+6+9delTGAG, 1 Gln257fs, 1 Val279fs, 1 Gln341X,
1 Thr278fs, 1 Cys314X, 1 c.709-3C>G homozygous, 1 Gln130fs, 1 Cys149fs, 1 Cys157fs, 1 Cys315X, 1 Asn188fs, 1 Val200fs, 1 Pro127fs.
610 Pro301Leu, 2 Gly272Val, 3 Arg406Trp, 1 Leu315Arg, 1 Val337Met, 1 Val287Ile, 1 Ser305Thr.
626 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Neurofilaments in Genetic Frontotemporal Dementia L.H. Meeter et al.
described, slightly modified, electrochemiluminescence
immunoassay with antibodies identical to those used in
the CSF ELISA (Data S1).31,32
Statistical analyses
Statistical analyses were performed in SPSS 21.0 for
Windows (Armonk, NY, USA) and GraphPad Prism 6
(La Jolla, California, USA) applying a significance level
of P < 0.05. NfL values with an intra-assay CV of >20%
(n = 1) and outliers (values > three standard deviations
from the mean: four CSF and two serum samples) were
excluded. CSF and serum NfL were analyzed using non-
parametric tests (Mann–Whitney U tests and Kruskal–
Wallis with Dunn’s post hoc tests). Since the data were
not normally distributed, and log-transformation did not
normalize the data, square root transformed CSF and
serum NfL were used to correct for age in all subjects
and disease duration in patients using analysis of covari-
ance (ANCOVA) with post hoc Bonferroni corrections
where appropriate. Spearman’s correlation coefficient (rs)
was used to correlate serum with CSF NfL, NfL levels
with clinical measures and CSF NfL with brain volumes,
the latter also with correction for gender and study site
(partial rank correlations). Diagnostic performance was
assessed by areas under the curve (AUC) with 95% con-
fidence intervals (CIs) obtained by receiver operating
characteristic (ROC) analyses, with optimal cut-off levels
at the highest Youden’s index (sensitivity + specificity-1).33
In analogy to the study of Lu et al.,18 survival in
patients was compared between NfL tertiles by Kaplan–
Meier curves and Cox regressions adjusted for age and
disease duration. NfL concentrations are described as
medians.
Results
Demographic and clinical data
The total group of 234 subjects consisted of 101 patients
(53 GRN, 29 C9orf72, 19 MAPT), 62 presymptomatic car-
riers (34 GRN, 14 C9orf72, 14 MAPT) and 71 controls
(Table 1, Fig. S1). Patients were older than presymp-
tomatic carriers (P < 0.001) and controls (P < 0.001).
GRN and C9orf72 patients were older than MAPT
patients (P = 0.01 and P = 0.04 respectively). The age at
onset in patients was highly variable ranging between 39
and 76 years and several presymptomatic carriers were
past their estimated age at onset. However, 50% percent
of the patients had an onset between 52 and 62 years;
and the age of both converters was close to the estimated
onset age. The disease duration in C9orf72 patients was
longer than in GRN patients (P = 0.007). The clinical
presentation was bvFTD (n = 60), PPA (n = 17), FTD-
ALS (n = 7), predominant memory phenotype (n = 4),
mild cognitive impairment (n = 4), progressive supranu-
clear palsy or corticobasal syndrome (n = 2), and demen-
tia not otherwise specified (n = 7).
NfL in CSF and in serum
CSF NfL levels in patients (6762 pg/mL) were more than
eight times higher than in presymptomatic carriers
(804 pg/mL) and controls (650 pg/mL, both P < 0.001,
Fig. 1A), without a difference between the latter two
groups (P = 0.46, Fig. S2A). The elevation was confirmed
after genetic stratification (Fig. 1B). GRN patients had
higher CSF NfL levels than C9orf72 and MAPT patients
(P < 0.001 and P = 0.004 respectively, Fig. 1B). CSF NfL
did not differ between the three presymptomatic groups
(P = 0.17, Fig. S2B). Correction for age in all subjects
and disease duration in patients on square root trans-
formed CSF NfL yielded similar P-values as without
transformation, except for presymptomatic C9orf72 cases
versus C9orf72 patient (before correction P < 0.001, after
correction P = 0.04, all corrected P-values are displayed
in Figure 1 and transformed data is presented in Fig. S3).
NfL levels in serum showed a similar pattern as in CSF,
with higher levels in patients (31.5 pg/mL) than in
presymptomatic carriers (3.5 pg/mL, P < 0.001) and con-
trols (2.9 pg/mL, P < 0.001, Fig. 1C), without a difference
between the latter two groups (Fig. S2C). Consistently,
the elevation was confirmed after genetic stratification.
GRN patients had higher serum NfL levels than MAPT
patients (P = 0.03, Fig. 1D), both did not differ from
C9orf72 patients. Serum NfL did not differ between the
three presymptomatic groups (P = 0.76, Fig. S2D). Cor-
rection for age and disease duration showed similar
results, except for the difference between presymptomatic
carriers and patients which showed only a trend for the
MAPT and C9orf72 mutations (both P = 0.11, Fig. 1D
and Fig. S3C and S3D), probably due to the small
groups.
Correlation between CSF and serum NfL
CSF NfL correlated strongly with serum NfL (Fig. 2A,
entire group rs = 0.87, P < 0.001). The correlations
were strongest in carriers (patients rs = 0.77, P < 0.001
and presymptomatic carriers rs = 0.83, P < 0.001),
whereas controls showed only a trend (rs = 0.50,
P = 0.06). Sample sets collected on the same day
showed slightly, although not significantly, stronger
correlations (n = 37, entire group rs = 0.90, presymp-
tomatic carriers rs = 0.90, and patients rs = 0.86, all
P < 0.001).
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Correlation with demographical and clinical
characteristics
Age correlated with CSF NfL levels in presymptomatic
carriers and controls (rs = 0.79, P < 0.001 respectively
rs = 0.58, P < 0.001), but not in patients (rs = 0.13,
P = 0.22). In serum, a similar pattern was found
(presymptomatic carriers rs = 0.46, P < 0.002, controls
rs = 0.70, P < 0.001, patients rs = 0.23, P = 0.19). Females
and males showed similar NfL levels (CSF P = 0.18,
serum P = 0.08). CSF NfL levels in patients correlated
positively with CDR and CDR-SB, but not with MMSE
or disease duration (Table 2, Fig. 2B); serum NfL corre-
lated positively with CDR-SB and not with MMSE or dis-
ease duration (Table 2). CSF NfL in four of the six
patients with concomitant ALS fell in the highest 20%
(Fig. 1A). Associations between NfL concentrations and
estimated onset in presymptomatic carriers are displayed
in Figure S2E and S2F.
CSF NfL levels versus brain volumes
Whole-brain volume as a percentage of TIV was lower in
patients than in presymptomatic carriers (P < 0.001) and
lower in presymptomatic carriers than in controls
(P = 0.04). Cortical volumes were lower in patients than
in presymptomatic carriers in all investigated areas, except
for occipital (all areas P < 0.001), without differences
between controls and presymptomatic carriers.
CSF NfL in carriers negatively correlated with whole-
brain volume (Fig. 2C) and with frontal, temporal, pari-
etal, insular and cingulate cortices (Table 3 and Fig. S4),
indicating smaller volumes in case of higher CSF NfL.
The analysis of patients only (n = 28) yielded significant
negative correlations for whole brain, frontal cortex, and
insular cortex. In presymptomatic carriers, negative corre-
lations were found for whole brain and frontal, temporal,
and parietal cortices. Subgroup analyses of scans from
presymptomatic and symptomatic carriers combined and
a CSF-MRI interval of 90 days or less, as well as correc-
tion for gender and age showed similar patterns, albeit
with lower correlation coefficients in the latter. Similar
results were obtained after correction for study site.
Unexpectedly, a positive correlation between NfL CSF
and occipital cortex volume was found in the patient
group.
In the subgroup of carriers with a follow-up scan after
CSF collection (7 patients and 10 presymptomatic carri-
ers, median time between scans 1.1 years [interquartile
range 1.0–2.1]) we found significant correlations between
CSF NfL and annualized rate of atrophy for whole brain,
frontal, temporal, parietal, cingulate, and insular cortices
(Table 3 and Fig. 2D).
Diagnostic performance
ROC analyses on CSF NfL levels showed a high AUC to
separate patients both from controls (AUC 0.99 [95% CI:
0.97–1.00]) and from presymptomatic carriers (AUC 0.97
[0.94–0.99]), with a sensitivity of 84% and specificity of
100% for a cut-off level of 2165 pg/mL (Fig. 1A). Lower
AUCs, although not significantly lower, were found for
serum NfL (patients versus controls 0.97 [0.93–1.00],
patients versus presymptomatic carriers 0.93 [0.87–0.98]).
Serum NfL had a sensitivity of 77% and a specificity of
98% to separate patients from presymptomatic carriers
(cut-off level of 18.0 pg/mL, Fig. 1C). To separate
presymptomatic carriers from controls, CSF NfL levels
showed an AUC of 0.65 (0.53–0.77) with a sensitivity of
40% and a specificity of 94% for a cut-off level of
1066 pg/mL (Fig. S2A); the AUC of serum NfL for con-
trols versus presymptomatic carriers was 0.63 (95% CI:
0.51–0.75, sensitivity 34% and specificity 97% at a cut-off
level of 8.3 pg/mL, Fig. S2C).
Survival analyses
The median survival after CSF collection of deceased
patients was 3.6 years (range 0.4–8.1, n = 34), the median
follow-up of alive patients was 2.8 years (range 0.4–10.7,
n = 38). High CSF NfL levels were associated with a poor
survival (estimated hazard ratio [HR] of 2.21 (95% CI:
1.30–3.77), P = 0.004, corrected for age and disease dura-
tion, Fig. 2E). This association was most prominent in
C9orf72 cases, even after correction for ALS (estimated
HR 24.59, P = 0.02, corrected for ALS, age, and disease
Figure 1. Neurofilament light chain (NfL) levels in presymptomatic carriers and patients. NfL in (A) cerebrospinal fluid (CSF) and (C) serum by
controls, presymptomatic carriers and patients; patients with concomitant amyotrophic lateral sclerosis are displayed as filled orange diamonds.
Upper blue dashed lines represent the cut-off line to separate presymptomatic carriers from patients at 2165 pg/mL for CSF (sensitivity 84%,
specificity 100%) and at 18.0 pg/mL for serum (sensitivity 77%, specificity 98%). Lower green dashed lines represent the cut-off line to separate
controls from patients at 1190 pg/mL for CSF (sensitivity 97%, specificity 98%) and at 9.3 pg/mL for serum (sensitivity 91%, specificity 100%).
NfL levels in (B) CSF and (D) serum specified by genetic group and clinical stage. Significances from the analysis of covariance analyses are
displayed (corrected for age in all comparisons and additionally for disease duration in the comparisons between affected genes in patients). In
Figure S3, graphs of the transformed data are shown. Ns, not significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 629
L.H. Meeter et al. Neurofilaments in Genetic Frontotemporal Dementia
0 5 10 15
0
50
100
Time from CSF collection (years)
P
er
ce
nt
su
rv
iv
al
0 5 10 15
0
50
100
Time from serum collection (years)
P
er
ce
nt
su
rv
iv
al
FE
0 5,000 10,000 15,000
55
60
65
70
75
80
CSF NfL (pg/ml)
W
ho
le
br
ai
n
vo
lu
m
e
(%
of
TI
V)
0 2,000 4,000 6,000 8,000
-2
0
2
4
6
8
10
CSF NfL (pg/ml)
In
su
la
ra
tr
op
hy
ra
te
(%
/y
ea
r)
DC
0.1 1 10 100
100
1,000
10,000
100,000
Serum NfL (pg/ml)
C
SF
N
fL
(p
g/
m
l)
0 5 10 15
0
5,000
10,000
15,000
20,000
25,000
Disease duration  (years)
C
SF
N
fL
(p
g/
m
l)
A B
Figure 2. Correlations between neurofilament light chain (NfL) levels and clinical or imaging data. (A) Correlation between serum and
cerebrospinal fluid (CSF) NfL, circles represent controls, squares represent presymptomatic carriers and triangles represent patients; filled data
points are collected on the same day; a log-scale is used for display purposes, one sample had a serum NfL of 0 pg/mL and is thus excluded from
the graph, but not from the analysis. (B) Correlation of CSF NfL with disease duration in patients (orange triangles). Correlations between CSF NfL
and (C) whole-brain volume and (D) insular annualized atrophy rate in presymptomatic carriers (blue squares) and patients (orange triangles).
Kaplan–Meier curves of (E) all patients with CSF available and (F) all patients with serum available; NfL levels were stratified into tertiles: the blue
upper lines represent the lowest tertiles, the green middle lines the middle tertiles and the orange lower lines the highest tertiles; information on
survival was available in 72 out of 86 patients with CSF and all patients with serum (n = 35).
630 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Neurofilaments in Genetic Frontotemporal Dementia L.H. Meeter et al.
duration). Dividing the cohort into two groups gave simi-
lar results; dividing into four groups gave major overlap
in CIs. Cox regressions on ‘raw’ CSF NfL confirmed the
association with mortality: HR 1.02 for each increase in
1000 pg/mL (P < 0.001). Serum NfL was also associated
with survival (estimated HR on tertiles 3.10, 95% CI:
1.09–8.76, P = 0.03, Fig. 2F, 14 deceased and 21 alive;
estimated HR on ‘raw’ serum NfL 1.02, P = 0.02); gene-
specific analyses in serum yielded no significant results.
Longitudinal samples
Longitudinal CSF samples of the two GRN converters,
showed a three- to fourfold increase in NfL levels over
conversion into the symptomatic stage (interval 3.1 and
2.0 years respectively; Fig. S5), with a 5.8-fold increase
(from 9.5 to 55.3 pg/mL) in serum samples available in
one converter. A decrease (48% in 1 year) in CSF NfL
of the third relative to the second sample was seen in the
symptomatic stage of one converter. Longitudinal CSF
samples of one patient and two presymptomatic carriers
showed a 0.8–1.5-fold change (Fig. S5); the CVs of all
described longitudinal samples were below 5%.
Discussion
The present study on a large cohort of carriers of patho-
genic GRN, MAPT or C9orf72 mutations showed
eight-fold higher CSF NfL levels in patients than in
presymptomatic carriers and controls. CSF NfL discrimi-
nated presymptomatic carriers from patients and might
be useful to determine conversion. Serum NfL correlated
highly with CSF NfL and showed a similar elevation in
patients. Additionally, NfL levels in patients correlated
with disease severity, brain atrophy, annualized brain
atrophy rate, and survival. Hence, NfL in CSF or blood
has the potential to serve as a biomarker for clinical dis-
ease onset and severity with a prognostic value.
The finding of elevated CSF and serum NfL levels in
patients, with a good diagnostic performance to separate
them from presymptomatic carriers, confirms the earlier
findings in small series of presymptomatic carriers.10,15
The strong correlation between CSF and serum NfL levels,
alike in ALS,15,18 suggests a promising role for serum NfL
as a biomarker, as blood collections are more patient
friendly than lumbar punctures. The trend for a lower
correlation between serum and CSF NfL in controls than
in mutation carriers is probably explained by the small
group in combination with a suboptimal sensitivity of the
Table 2. Association between neurofilament light chain levels (in
cerebrospinal fluid [CSF] and serum) and clinical characteristics or
scales in patients.
CSF Serum
rs P n rs P n
Disease duration 0.07 0.50 841 0.33 0.06 341
MMSE 0.19 0.14 66 0.28 0.13 30
CDR 0.33 0.04 40 0.36 0.08 25
CDR-SB 0.60 0.001 27 0.53 0.02 19
MMSE, mini-mental state examination; CDR, clinical dementia rating
scale; CDR-SB, clinical dementia rating scale sum of boxes.
1In two patients with CSF and one patient with serum, disease onset
was unknown.
Table 3. Correlations of cerebrospinal fluid (CSF) neurofilament light chain (NfL) with MRI volumes.
Cross-sectional MRI
Longitudinal MRI
All carriers,
n = 55
Patients,
n = 28
Presymptomatic carriers,
n = 27
Annualized atrophy rate,
all carriers, n = 17
Whole-brain volume rs 0.78 0.66 0.43 0.79
P <0.001 <0.001 0.03 <0.001
Frontal rs 0.72 0.54 0.59 0.64
P <0.001 0.003 0.001 0.006
Temporal rs 0.51 0.001 0.50 0.74
P <0.001 1.00 0.008 0.001
Parietal rs 0.67 0.24 0.41 0.76
P <0.001 0.23 0.03 <0.001
Occipital rs 0.004 0.56 0.28 0.48
P 0.98 0.002 0.16 0.05
Cingulate rs 0.43 0.32 0.21 0.72
P 0.001 0.10 0.29 0.001
Insula rs 0.63 0.59 0.24 0.83
P <0.001 0.001 0.23 <0.001
Correlations of CSF NfL with whole-brain and gray matter volumes at baseline are displayed in the first three columns. Correlations of CSF NfL
with annualized atrophy rate from longitudinal scans are displayed in the last column.
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 631
L.H. Meeter et al. Neurofilaments in Genetic Frontotemporal Dementia
serum assay in the lower range of values. Forthcoming
new platforms have a higher sensitivity in this lower
range; however, this will probably not influence the con-
clusions of this study, as genetic FTD patients showed
high serum NfL levels.
The higher NfL levels in GRN patients than in MAPT
patients are supported by earlier findings of higher CSF
NfL in cases with TDP-43-pathology than with tau-
pathology,34 and suggest mutation-specific underlying
mechanisms. An intriguing question is whether NfL levels
merely reflects the extent of neuronal cell death or white
matter involvement, as has been reported in FTD-GRN.35
Correlation of NfL levels with white matter damage has
been found in FTD, AD, vascular dementia, and
ALS.10,36,37 On the other hand, neurofilament proteins are
also integral components of synapses with an important
role in receptor-specific synaptic plasticity.17 Therefore,
mutation-specific NfL elevation may reflect distinct
pathophysiological mechanisms with a more white matter
and/or synaptic origin of the disease process in GRN
mutations. The wide range of NfL levels in our C9orf72
patients correlated with the clinical phenotype, with
mostly high levels in subjects with concomitant ALS and/
or fast progression and low levels in patients with a slow
progression. This is in line with high NfL levels in genetic
ALS (half C9orf72 carriers) and sporadic ALS, the latter
correlating with a fast progression and DTI abnormali-
ties.15,18,37 Although DTI analyses across multiple centers
are at the moment challenging to harmonize, future DTI
studies combined with NfL levels in the different genetic
subtypes of FTD, may elucidate the relationship with
white matter integrity.
The identified correlations of NfL levels with disease
severity and survival in genetic FTD patients are also in line
with earlier reports in sporadic FTD, AD, and ALS.10,11,13,18
Specifically, the association of high NfL levels with a poor
survival could serve as a meaningful prognostic clinical
tool. The lack of correlation between NfL levels and age in
patients as opposed to the controls and presymptomatic
carriers, is likely explained by the magnitude of the disease
effect outweighing the effect of age.
The negative correlation between CSF NfL and brain and
cortical volumes is in line with findings in a cohort of
mainly sporadic FTD patients in which a negative correla-
tion with gray and white matter volume was found.10 This
supports the hypothesis that NfL levels reflect the extent of
neurodegeneration.16 So far, the positive correlation
between CSF NfL and occipital volume in our patients is
difficult to explain. Perhaps gene-specific differences are
underlying, since the occipital lobe is often affected in
C9orf72,38 which is associated with relatively low NfL levels
in current study, and spared in GRN, showing high NfL
levels; however groups were too small for gene-specific
analyses. The correlation between CSF NfL and annualized
rate of atrophy in the subset of carriers with two consecu-
tive scans, supports the observed prognostic value of NfL
levels in the cross-sectional analysis. Larger future studies
are needed to determine whether gene-specific rates of
atrophy, as found in the study by Whitwell et al.,39 could
be correlated with corresponding NfL levels.
The observed three- to fourfold increase in CSF NfL
levels within 3 years in our converters and normal levels
over the entire presymptomatic phase in our large series of
healthy mutation carriers, gives a first indication of the
time period in which NfL increases. Although the time to
onset is difficult to estimate, due to varying age at onset
among families, we showed only a small increase in asymp-
tomatic subjects approaching their estimated onset. The
elevation in NfL levels suggests a rather explosive nature of
the disease process, at least for GRN mutations, in which a
rapid breakdown of the neuroaxonal compartment takes
place, instead of a more linear disease progression. Similar
dynamics are suggested in ALS.40 NfL levels in CSF and,
according to our data, likely also in serum may thus serve
as a biomarker for an active disease process coinciding with
the onset of clinical symptoms in genetic FTD.
Major strengths of our study are the large series of
presymptomatic carriers and patients with genetic FTD
and the multimodal approach in correlating clinical and
imaging data with a fluid biomarker. NfL determinations
were performed in one laboratory which excludes an
important source of variability.41 Additionally, studying
genetic FTD allows us to investigate the earliest disease
processes in subjects with a known underlying pathology,
which is ideal to identify biomarkers. An important weak-
ness in our study was the interval between collection of
CSF, serum, and MRI scanning. However, results were
similar in the carriers with an shorter interval between
CSF sampling and MRI scanning as well as similar corre-
lations in serum and CSF samples collected on the same
day. Secondly, combining subjects from multiple centers
resulted in variability regarding sample collection, how-
ever NfL measurements in CSF are known to be robust to
preanalytical variables.42 Lastly, too few samples were
available to draw conclusions on longitudinal dynamics
and the meaning of the decrease in CSF NfL in one con-
verter at a third time point. The relatively stable NfL
levels over time in ALS might indicate that release and
accumulation of NfL is counterbalanced by clearing
mechanisms.18 Additionally, in multiple sclerosis CSF NfL
have shown to dynamically decrease after therapeutical
interventions, which suggests a potential to serve as a
pharmacodynamic biomarker in FTD as well.14 Longitudi-
nal NfL studies in CSF and serum in FTD are needed to
determine (1) whether yearly NfL measurements are a
robust biomarker for conversion; (2) changes throughout
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the disease process; and (3) the potential to measure
pharmacodynamic response to interventions. In our opin-
ion however, our cross-sectional results clearly discrimi-
nated presymptomatic carriers from patients, making
longitudinal studies interesting, but not necessary before
the application in the clinic.
In conclusion, NfL in both CSF and serum is a promis-
ing biomarker for disease onset, severity, and survival in
genetic FTD. Longitudinal studies are warranted to assess
dynamics over time and thereby the usefulness of NfL for
clinical trials in FTD.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Data S1. Methods.
Figure S1. Patient numbers per collected material and
available MR-imaging. Displayed numbers are after exclu-
sion of outliers. *Three subjects were excluded from the
analysis on the correlation between serum and CSF
because the interval between serum and CSF collection
was longer than 1 year (1 control, 2 presymptomatic
carriers).
Figure S2. NfL levels in presymptomatic carriers and con-
trols. NfL levels in (A) CSF and (C) serum by controls
and presymptomatic carriers. Green dashed lines repre-
sent the cut-off line to separate controls from presymp-
tomatic carriers at 1066 pg/mL for CSF (sensitivity 40%,
specificity 94%) and at 8.3 pg/mL for serum (sensitivity
34%, specificity 97%). NfL levels in (B) CSF and (D)
serum in controls and presymptomatic carriers specified
by genetic group (GRN, C9orf72 and MAPT). Signifi-
cances from the analysis of covariance analyses are dis-
played (corrected for age). Association between (E) CSF
NfL and (F) serum NfL and time from estimated onset in
controls (red circles) and presymptomatic carriers (GRN
filled blue triangles, C9orf72 filled blue squares, MAPT
filled blue diamonds). One young individual is omitted
from the graphs, but not from the analyses, to prevent
disclosure of the genetic status. Presymptomatic carriers
with CSF NfL values (n = 9) and serum NfL values
(n = 14) of >2SD above the mean of controls were closer
to or beyond the estimated onset (CSF mean 1.1 years
and serum mean 0.8 years after estimated onset) than the
presymptomatic carriers below that cut-off (CSF mean
10.2 years and serum 9.1 years to estimated onset, both
P < 0.001). In presymptomatic carriers, both CSF and
serum NfL significantly correlated with time to onset or
estimated onset (CSF rs = 0.69, P < 0.001 and serum
rs = 0.57, P < 0.001). Ns, not significant.
Figure S3. Square root transformed NfL levels in
presymptomatic carriers and patients. Square root of NfL
in (A) CSF and (C) serum by controls, presymptomatic
carriers and patients. Additionally, square root of NfL
levels in (B) CSF and (D) serum specified by genetic
group and clinical stage. Significances from the analysis of
covariance analyses are displayed (corrected for age in all
comparisons and additionally for disease duration in the
comparisons between affected genes in patients). Ns, not
significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Figure S4. Correlation between CSF NfL and MR-imaging
data. (A) Correlation of whole-brain volume with CSF
NfL in controls (red circles) and presymptomatic carriers
(GRN blue filled triangles, C9orf72 blue filled squares,
MAPT blue filled diamonds). Correlations between CSF
NfL and (B) frontal lobe volume and (C) temporal lobes
volume in presymptomatic carriers (blue squares) and
patients (orange triangles).
Figure S5. Longitudinal CSF NfL samples. Longitudinal
samples of two converters (green and light blue lines),
two presymptomatic carriers (dark blue lines) and one
patient (orange line), plotted by time from onset or esti-
mated onset in years.
636 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Neurofilaments in Genetic Frontotemporal Dementia L.H. Meeter et al.
